No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Zhejiang Shouxiangu Pharmaceutical (603896.SH): Has established accounts such as "Zhejiang Shouxiangu Pharmaceutical" on the Xiaohongshu platform for brand promotion.
On January 21, Glenwood reported that Zhejiang Shouxiangu Pharmaceutical (603896.SH) stated on the investor interaction platform that the WeChat "gift giving" feature by default supports most WeChat mini-store commodities, except for jewelry, Education training categories, and items priced over 0.01 million yuan. If you would like to use the WeChat "gift giving" feature to gift company products to friends, please update WeChat to the latest version and visit the "Zhejiang Shouxiangu Health Pharmacy" WeChat mini-store to make your selection. At the same time, the company has established accounts on Xiaohongshu for "Zhejiang Shouxiangu", "Zhejiang Shouxiangu wall-removed reishi spore powder", "Zhejiang Shouxiangu health products", "Zhejiang Shouxiangu health foods", and "Zhejiang Shouxiangu tourism".
These 4 Measures Indicate That Zhejiang Shouxiangu Pharmaceutical (SHSE:603896) Is Using Debt Extensively
Zhejiang Shouxiangu Pharmaceutical (603896.SH): Its main business does not involve secondary dimension cultural and creative products, games, and entertainment industry.
Gelonghui November 28th, zhejiang shouxiangu pharmaceutical (603896.SH) stated on the investor interaction platform that the company has its own cartoon fairy image commodities, but the company's main business does not involve secondary-dimensional cultural and creative products, games, and entertainment industry.
Zhejiang Shouxiangu Pharmaceutical (603896.SH): Intends to change some of the raise investment projects and postpone.
Shouxiangu (603896.SH) announced on November 27 that it plans to redirect some of the originally allocated funds to the "Shouxiangu Health Industry Park Health Food Phase II Construction Project (Production Line Construction)" to the "Smart Park Upgrade Project", with the total amount of redirected funds being 80.532 million yuan, accounting for 20.23% of the total amount of funds raised for the "Shou 22 Convertible Bonds". At the same time, the funds have generated cash management income and interest of 5.5861 million yuan, with the specific amount subject to the balance of the bank account on the day of fund transfer. Shouxiangu Health Industry Park Smart Park Upgrade Construction Project
Zhejiang Shouxiangu Pharmaceutical (SHSE:603896) Will Be Hoping To Turn Its Returns On Capital Around
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.'s (SHSE:603896) Prospects Need A Boost To Lift Shares
